Loading stock data…
Protalix BioTherapeutics, Inc. (PLX)
$2.65-0.02 (-0.75%)
Market ClosedLast close Sep 8
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protalix BioTherapeutics, Inc. in the Healthcare sector is trading at $2.65 with a market capitalization of $214M. Wall Street consensus targets $11.00 (2 analysts), implying a +315.1% move over the next 12 months. The stock is currently 17% below its 52-week high of $3.19, remaining 18.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +315.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33.75M↑ | $9.12M↓ | $17.85M↑ | $15.66M↑ | $10.11M |
| Gross Profit | $29.62M↑ | $4.50M↓ | $9.53M↓ | $9.79M↑ | $1.93M |
| Operating Income | $21.15M↑ | -$4.66M↓ | $2.13M↑ | $1.17M↑ | -$4.14M |
| Net Income | $18.32M↑ | -$5.50M↓ | $2.35M↑ | $164,000↑ | -$3.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Ele...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$213.51M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.52
Beta
Defensive asset. Lower volatility than the S&P 500.
0.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.53%
Volume
Today's trading volume
907,641
Recent News
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
Revenue climbs 27% year-over-year, driven by higher Elfabrio sales to Chiesi, while the company advances its promising PRS-115 gout program.
3 Penny Stocks With Market Caps Larger Than $100M To Consider
The market has climbed 1.2% in the last 7 days and an impressive 29% over the past year, with earnings forecasted to grow by 17% annually. While penny stocks might seem like a relic from earlier market eras, they offer a unique opportunity for growth at lower price points, especially when backed by strong balance sheets and solid fundamentals. In this article, we explore several penny stocks that stand out as hidden gems with potential for impressive returns.
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
Protalix BioTherapeutics Inc (PLX) reports a profitable quarter with significant milestone achievements and reaffirms its 2026 revenue guidance.